Illumina, Inc. (NASDAQ:ILMN) EVP Marc Stapley sold 1,000 shares of the firm’s stock in a transaction on Thursday, December 6th. The stock was sold at an average price of $329.69, for a total transaction of $329,690.00. Following the completion of the sale, the executive vice president now owns 7,857 shares in the company, valued at $2,590,374.33. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Marc Stapley also recently made the following trade(s):
- On Wednesday, November 7th, Marc Stapley sold 1,000 shares of Illumina stock. The stock was sold at an average price of $336.68, for a total transaction of $336,680.00.
Shares of Illumina stock traded down $12.91 during trading on Friday, hitting $321.41. 1,086,450 shares of the company’s stock traded hands, compared to its average volume of 1,009,090. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.24 and a current ratio of 2.46. Illumina, Inc. has a twelve month low of $207.51 and a twelve month high of $372.61. The firm has a market cap of $49.15 billion, a P/E ratio of 80.35, a price-to-earnings-growth ratio of 2.48 and a beta of 1.09.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.26. Illumina had a net margin of 21.09% and a return on equity of 27.10%. The business had revenue of $853.00 million for the quarter, compared to analyst estimates of $825.65 million. During the same period in the previous year, the business earned $1.11 EPS. The firm’s revenue was up 19.5% on a year-over-year basis. On average, equities analysts forecast that Illumina, Inc. will post 5.75 earnings per share for the current fiscal year.
Several analysts have issued reports on the stock. UBS Group assumed coverage on shares of Illumina in a research report on Tuesday, October 9th. They issued a “neutral” rating and a $340.00 price target on the stock. Zacks Investment Research lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Wednesday, October 24th. BidaskClub lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. Deutsche Bank raised their price target on shares of Illumina to $350.00 and gave the stock a “buy” rating in a research report on Friday, October 12th. Finally, Piper Jaffray Companies raised their price target on shares of Illumina to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 2nd. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $330.94.
Several institutional investors have recently modified their holdings of ILMN. Moneta Group Investment Advisors LLC boosted its position in shares of Illumina by 2,670.0% during the 2nd quarter. Moneta Group Investment Advisors LLC now owns 9,695 shares of the life sciences company’s stock valued at $107,000 after acquiring an additional 9,345 shares in the last quarter. Sun Life Financial INC boosted its position in Illumina by 152.5% in the second quarter. Sun Life Financial INC now owns 399 shares of the life sciences company’s stock valued at $111,000 after buying an additional 241 shares in the last quarter. Highstreet Asset Management Inc. acquired a new position in Illumina in the third quarter valued at about $112,000. Migdal Insurance & Financial Holdings Ltd. boosted its position in Illumina by 3,192.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 428 shares of the life sciences company’s stock valued at $120,000 after buying an additional 415 shares in the last quarter. Finally, Ancora Advisors LLC acquired a new position in Illumina in the third quarter valued at about $145,000. Institutional investors and hedge funds own 88.91% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Illumina, Inc. (ILMN) EVP Marc Stapley Sells 1,000 Shares” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/12/08/illumina-inc-ilmn-evp-marc-stapley-sells-1000-shares.html.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
See Also: How to invest in a bear market
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.